Generic Zantac Distribution Halted Worldwide; Contamination Concerns

This article was originally published on Medscape.com

Written by Marcia Frellick | Published September 18, 2019

Distribution of generic versions of the popular heartburn drug ranitidine (Zantac, Novartis) is being halted in markets worldwide by the manufacturer, according to a spokesperson for Novartis, after findings that the medication may have become tainted with a cancer-causing agent.

Dana Kahn Cooper, a spokesperson for Novartis, told Medscape Medical News: “A precautionary distribution stop of all Sandoz ranitidine-containing medicines in all our markets will remain in place under further clarification. This includes capsules in the USA. Our internal investigation is ongoing to determine further details. In case of concerns, adequate additional measures will be implemented in alignment with relevant Health Authorities as required.” Continue reading…

Heather Tick2019-09-20T09:48:29-07:00September 20th, 2019|Nutrition|

About the Author: Heather Tick

For over 20 years Dr. Tick has dedicated herself to researching evidence-based holistic treatments for pain and inflammation. A multiple-book author, including the highly acclaimed Holistic Pain Relief - An In-Depth Guide to Managing Chronic Pain, Dr. Tick empowers her patients to live free of pain and full of life. She is the first holder of the prestigious Gunn-Loke Endowed Professorship of Integrative Pain Medicine at the University of Washington and a Clinical Associate Professor at the University of Washington in the departments of Family Medicine and Anesthesiology & Pain Medicine.